Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.
Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.